CCL16 (C-C motif chemokine ligand 16), also known as HCC-4 or LEC, is a member of the CC chemokine family involved in immune regulation and inflammatory responses. It is encoded by the *SCYA16* gene in humans and is primarily produced by dendritic cells, macrophages, and epithelial cells in tissues such as the liver, spleen, and lungs. CCL16 exerts its biological effects by binding to chemokine receptors CCR1. CCR2. CCR5. and CCR8. which are expressed on immune cells like monocytes, T cells, and neutrophils.
This chemokine plays a role in recruiting leukocytes to sites of inflammation, modulating angiogenesis, and promoting tissue repair. It also exhibits antimicrobial and antitumor activities, making it a potential therapeutic target. Dysregulation of CCL16 has been linked to pathologies including chronic inflammation, autoimmune diseases (e.g., rheumatoid arthritis), and cancer progression.
CCL16 antibodies are research tools used to detect or neutralize CCL16 in experimental settings. They enable the study of its expression patterns, signaling pathways, and interactions with receptors. Such antibodies are critical for elucidating CCL16’s role in disease mechanisms and evaluating its diagnostic or therapeutic potential. Commercial CCL16 antibodies are typically validated for applications like ELISA, Western blotting, and immunohistochemistry, aiding both basic research and drug development efforts.